Non-clinical studies are an essential part of the development of novel radiotracers and theranostics.

Increasing regulatory focus on the scientific relevance and translational justification of preclinical data means that careful consideration must be given to study design, model selection, and the overall impact of generated data on the downstream clinical development pathway.

Whether evaluating basic proof-of-principle biodistribution, tissue pharmacology, dosimetry or therapeutic efficacy, CITRAS provides expert support in both the design and critical review of non-clinical programmes.